COUCH Health has released new research exploring reasons behind the underrepresentation of ethnic minorities in US & UK clinical trials. Also addressed are how clinical trial communication strategies can be improved to better engage people from diverse backgrounds and ethnicities.
COUCH Health’s research findings suggest that participation from ethnic minorities continues to be low, even while COVID-19 has raised awareness of the importance of clinical trials among potential recruits and as the pharmaceutical industry has begun to tackle its diversity and inclusion problem. Many participants expressed their mistrust in so-called Big-Pharma, concern about being exploited and dehumanized, suspicion over the financial motives of the pharmaceutical industry, and disparities in the quality of care they might receive.
This research follows on from a study based in the United Kingdom, which found a similar reluctance from ethnic minorities to participate in clinical trials in the country. Both studies make several recommendations for better engaging potential recruits, including reaching out to community leaders, building tailored communication strategies per ethnic group, and providing complete information and transparency at every stage of the process.
For more information, click here.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.